SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Financial Collapse of 2001 Unwinding -- Ignore unavailable to you. Want to Upgrade?


To: elmatador who wrote (4378)2/28/2020 10:35:16 AM
From: Dr. Voodoo2 Recommendations

Recommended By
3bar
elmatador

  Read Replies (2) | Respond to of 13794
 
Hi elmat! Coronavirus Update:

Finally out from under work deluge,,,very busy last few weeks finishing up customer projects in USA before hopping on plane,,, now just getting back to planned re-entry into market and enjoying smiles in thailand.

Vaccine trials starting in USA: efficacy-be-damned a shot will be in order,,, as even 50-60% reduction is a substantial savings over large scale drowning. Estimate at least 4-6 months,,, unless china wins race by on-the-fly human trial, polio, etc style haste.

Antivirals-- as expected showing efficacy. GILD best choice here,,,, given current death rate,,, will be nibbling here when bottom is in. GILD purchase of Pharmasset looking super smart here,,now owns monopoly on discovery library gold mine.

Multi-Multi-Ton-Scale manufacture of somethingvir,,, not yet even ready,,, as even simple paper can't be kept on shelves per,,, amazon,, even at american price vs. chinese price. lead time for such 3 months for big dent,,,6+ months for all, no matter can build hospital in 6 days or 6 hours. Simply not simple,,, as supply chain has mortal sucking chest wound,,, and india is only alternative. pretty much guarantees modi a seat at the main table for now and forever. See below,,, as siblings,,, india-pakistan,,, iran-iraq,, north korea-china-south-korea,,, all now dressed as twinsies,,, and ready for long car ride on a hot day.

Disconcerting information world-wide

0.) Thailand,,, masks not really everywhere, thai's making memes on social media, having chuckle at world expense regarding thai superstition vs. western superstition and fondness for cruise ships. for the most part feel safe here,,, entry into thailand through NRT,,, was business as usual.

1.)USA: Virus patient in Northern California on the loose, with no-known source. very very troubling. This is likely sole reason for CDC dire warnings. Overall, damage to US and modern

I-I-I

2.) Italy. Tend to think initial result very very bad,,, but final outcome at least can be trusted.
3.) India. Discussing with Indian professor yesterday, both of us lamenting minimal news of outbreak ahead of orangemanbad arrival. Main economic drivers of travel direction for chinese,,,, not going over mountain range, so less concern for rural spread. surprised haven't seen more cases in metro hyderabad, mumbai, etc. at this point, very very suspect,,, unless genes conferring desire for lamb korma, also confer resistance to viral cell entry.
4.) Iran. American non-intelligence intelligence must be kicking self, as willingness of Iranians to serve as incubator was underestimated,,,, when trust but verify was so close,,, and now,, so far away. This can be only not good,,, Options are now,,, totalitarian crackdown e.g. stay at home,,, do-not-go-out-or-be-shot, or do-not-go-out-and-self-drowning.. This is bad, and will only get much much worse. There is no political way to paint this,,, it could quite easily be catalyst for major middle east conflict,,, as on-the-street iranian access to pitchforks, and mischief is just a matter of focus, not physical barrier, and border/powder keg Iraq,,,not helping.
5.) North Korea/South Korea/China Border--- long range concern,,, combo of 2.3.4.

6.) Japan case of re-infection,,, too early to tell,,, recovered may not have been recovered, or,,, as HSV, HIV recovered is never-quite-gone... This is something to monitor, because if latter case,,, then dawn tinfoil hat, crawl under chair, and wait for TEOTWAKI,,,, Even out of 80K cases, and 3300 recovered,,, is not enough to predict yet,,, and if recovered is never-quite-gone, human new normal will be very-very different.

As TJ says,,,but have not yet checked up,,, suspect as always,,, he has followed script,,, buy gold, for it is cheap,,, pd, and pt about to get cheaper,,, oil, even more so,,,and heading for even more-more-so.




To: elmatador who wrote (4378)3/4/2020 9:35:57 AM
From: Dr. Voodoo  Read Replies (1) | Respond to of 13794
 
fiercepharma.com

Target Validation in last 15 years--showing more benefit in the clinic.

Pharma Asia


China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines

by
Angus Liu |
Mar 4, 2020 6:18am



Roche has donated $2 million worth of Actemra to China before the anti-inflammatory med was officially added to Chinese authorities COVID-19 treatment guidelines. (Roche)

ShareFacebookTwitterLinkedInEmailPrint

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage.

Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commission said in its updated treatment guidelines (Chinese) for COVID-19 released Wednesday.

The Swiss drugmaker has donated CNY 14 million ($2 million) worth of Actemra to China, its local operations said in a blog post (Chinese) Monday, as the country continues to seek out older drugs that may help battle the disease at its epicenter.

Roche made the donations last week, days after a scientist at the Chinese Academy of Sciences said at a government press conference that promising results had been observed in 14 serious and critically ill patients treated with existing meds—including for arthritis—at a hospital affiliated with the University of Science and Technology of China (USTC).

USTC soon unveiled that the regimen includes Actemra. Scientists there have started a randomized clinical trial evaluating the drug’s application. According to Chinese Clinical Trial Registry, investigators aim to enroll 188 patients, with half on Actemra.

Actemra doesn’t directly kill the novel coronavirus, now dubbed SARS-CoV-2. It’s known as an inhibitor of the receptor of interleukin 6 (IL-6), a proinflammatory cytokine. In the disease COVID-19, the body may respond to the pathogen by overproducing immune cells and their signaling molecules in a dangerous phenomenon called cytokine storm. Similar lung inflammation happened in SARS patients during the 2003 outbreak, mainly in China.

USTC scientists and other research groups have recently fingered IL-6 as a main culprit in that immune overreaction among COVID-19 patients, hence the Actemra clinical trial. In 2017, the FDA also greenlighted Actemra to treat cytokine release syndrome—a form of cytokine storm—caused by CAR-T treatment.

In its previous treatment guidelines, Chinese authorities have already included elevated IL-6 level as an indicator of disease worsening. And in its current update, Actemra’s use is limited to patients with that marker.

In 2019, Actemra grew sales by 8% at constant currencies to reach CHF 2.31 billion ($2.42 billion), ranking sixth among Roche’s top-selling drugs.

Besides Actemra, Sanofi and Regeneron also have Kevzara, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis. In a statement sent to FiercePharma, a Sanofi spokesperson said the French drugmaker is “currently exploring Kevzara for severe COVID-19.” Sanofi’s in the process of gaining full rights to that med amid a collaboration overhaul.

During the ongoing outbreak, Chinese researchers have been trying to repurpose several existing meds to tackle either the coronavirus itself or the disease it causes. AbbVie’s fixed-dose HIV drug Kaletra (Aluvia), a combination of antivirals lopinavir and ritonavir, is also recommended. So is an influenza remedy Arbidol (umifenovir), which is not approved in Western countries.

Meanwhile, Gilead Sciences’ investigational remdesivir has so far been viewed as the most promising drug against COVID-19. The drug’s being studied in two clinical trials in China’s Hubei province, the epicenter of the outbreak. The National Institute of Allergy and Infectious Diseases is leading one in the U.S. And Gilead just initiated two additional phase 3 trials with plans to enroll about 1,000 patients, mainly in Asian countries.

Editor's Note: The story has been updated with a statement from Sanofi.